Common Shares, No Par Value
- Symbol
- BHC
- Exchange
- NYSE
- Classification
- COMMON
Current Report · Items 2.02, 9.01 · 8-K
Bausch Health Companies Inc
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On April 29, 2026, Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter ended March 31, 2026 and certain other financial information as of and for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.…
Company context
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
Current securities
Registered securities in this filing
Bausch Health Companies Inc. · 8-K · Filed 2026-04-29
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On April 29, 2026, Bausch Health Companies Inc. (the “Company”) issued a press release announcing results of operations for the quarter ended March 31, 2026 and certain other financial information as of and for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference. This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 do not constitute an offer to sell or the solicitation of an offer to buy any securities.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Filed exhibits (1)
EX-99.1 2 ex991-q1x2026.htm EX-99.1 Document Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS • First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year period • GAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment charge • GAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year period • Adjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32% • Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2026 RESULTS • Delivered twelfth consecutive quarter of year-over-year Revenue growth and Adjusted EBITDA (non-GAAP)1 growth, with …
Open exhibit ↗